TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03597542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs and Carbohydrates
Description: Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs and Carbohydrates
Description: Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
Study: NCT03005483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Orthopedic Surgery was applied for the treatment of osseous disorders

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orthopedic Surgery was applied for the treatment of osseous disorders
Study: NCT02884219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Expectative Management
Description: Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
Study: NCT00588341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient.
Study: NCT03230071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMBCZG
Description: 0.1g per pill which contains 14mg TMBCZG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMBCZG
Description: 0.1g per pill which contains 14mg TMBCZG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMBCZG
Description: 0.1g per pill which contains 14mg TMBCZG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.1g per pill which contains 0mg TMBCZG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: 0.1g per pill which contains 0mg TMBCZG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: 0.1g per pill which contains 0mg TMBCZG
Study: NCT03472859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOTOLASE
Description: This is the investigational yellow laser (PHOTOLASE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOTOLASE
Description: This is the investigational yellow laser (PHOTOLASE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTP
Description: This is the traditional green laser (KTP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTP
Description: This is the traditional green laser (KTP)
Study: NCT03011554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Miniature Telescope (IMT)
Description: Monocular implantation of the IMT.
Study: NCT03373500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary salt reduction
Description: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
Study: NCT04448821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Single administration of metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Single administration of metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Nilotinib
Description: Coadministration of metformin and nilotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Nilotinib
Description: Coadministration of metformin and nilotinib
Study: NCT01028261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-433
Description: Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
Study: NCT03352934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
Study: NCT01462162

Intervention type: DRUG
Intervention: Tocilizumab
Study: NCT00058019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study: NCT04481828

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastric resection with lymph node dissection(D1+,D2) for stomach cancer.

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
Study: NCT00684762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg Tablets
Description: Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol (Pletal®) 100 mg Tablets
Description: Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
Study: NCT02374632

Intervention type: OTHER
Group type: OTHER
Intervention: Meal tests after saline injection
Description: Fixed breakfast meal and ad libitum lunch meal

Intervention type: OTHER
Group type: OTHER
Intervention: Meal tests after saline injection
Description: Fixed breakfast meal and ad libitum lunch meal

Intervention type: OTHER
Group type: OTHER
Intervention: Meal tests after octreotide injection
Description: Fixed breakfast meal and ad libitum lunch meal

Intervention type: OTHER
Group type: OTHER
Intervention: Meal tests after octreotide injection
Description: Fixed breakfast meal and ad libitum lunch meal

Intervention type: OTHER
Group type: OTHER
Intervention: Sham feeding

Intervention type: OTHER
Group type: OTHER
Intervention: Sham feeding
Study: NCT04976114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Story book with information about surgery techniques
Description: Presurgery use of Story book. The parents with the child read a book with information about surgery techniques the days before surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video with information about surgery techniques
Description: Presurgery use of video. The parents with the child watch a video with information about surgery techniques the days before surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Story book and Video with information about surgery techniques
Description: Presurgery use of video and story book. The parents with the child watch a video and read a book (both) with information about surgery techniques the days before surgery.
Study: NCT02360631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Health education counseling will be provided to all participants.
Study: NCT01446133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day by mouth daily beginning on Day 9 of cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day by mouth daily beginning on Day 9 of cycle 1.
Study: NCT03142152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System
Description: The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Directed Heart Failure Medication
Description: Heart failure medication per ACC/AHA guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline Directed Heart Failure Medication
Description: Heart failure medication per ACC/AHA guidelines
Study: NCT04368039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Oxygen
Description: 40% FiO2 for 4 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21% FiO2 for 4 weeks
Study: NCT02523066

Intervention type: DEVICE
Intervention: Magna Ease
Description: This study is non-intervention
Study: NCT02734680

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy(CCRT)
Description: Radiation and take gemcitabine(GEM)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy(SBRT)
Description: Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Taking S-1 orally after radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Taking S-1 orally after radiation
Study: NCT03541772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin-Viusid®
Description: Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
Study: NCT04244435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: coronary artery bypass grafting with and without cardiopulmonary bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: coronary artery bypass grafting with and without cardiopulmonary bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG
Description: coronary artery bypass grafting with and without cardiopulmonary bypass

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thoracic epidural analgesia
Description: thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: analgesia of opioids
Description: Opioids will be used for perioperative analgesia
Study: NCT03292601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cinch Smart Strap
Description: The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinch Mobile App
Description: The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
Study: NCT02872298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Lung Denervation (TLD)
Description: The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
Study: NCT04047511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRTierOne
Description: As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group general fitness training
Description: A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group general fitness training
Description: A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Psychoeducation
Description: A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
Study: NCT01441817

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal fixation
Description: Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
Study: NCT03154372

Intervention type: OTHER
Group type: OTHER
Intervention: Expert supervised practice with validated metrics

Intervention type: OTHER
Group type: OTHER
Intervention: self guided practice with validated metrics
Study: NCT03018002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iSTAR
Description: Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results.
Study: NCT04627519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhea Health Tone®
Description: Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
Study: NCT01216163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Ibuprofen
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Single-dose of acetaminophen (1000mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo
Study: NCT00152009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (Guanfacine hydrochloride) (2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (3 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (4 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03597035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
Study: NCT02786264

Intervention type: DRUG
Intervention: Dexmedetomidine with propofol
Description: A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.

Intervention type: DRUG
Intervention: Propofol
Description: A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.

Intervention type: DRUG
Intervention: Propofol
Description: A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
Study: NCT02139657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIG-C
Study: NCT04618263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
Study: NCT01222429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegan diet
Description: Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diet following ADA guidelines
Description: participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
Study: NCT00993824

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colesevelam HCl
Description: 3.75 grams of colesevelam HCl (6 tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colesevelam HCl
Description: 3.75 grams of colesevelam HCl (6 tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01749072

Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib group
Description: Gefitinib 250mg once per day until the progression disease or intolerant side effects

Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine, Ifosfamide, Mesna
Description: Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
Study: NCT03148236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mL infused over 30 minutes
Study: NCT01406002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: oral